A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)

NCT05775094 Phase 1 ACTIVE_NOT_RECRUITING

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with multiple myeloma (MM).

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1
Status	ACTIVE_NOT_RECRUITING
Enrolment	10
Start date	2023-03-07
Completion	2027-03

Conditions

• Osteoporosis
• Multiple Myeloma

Interventions

• Romosozumab

Primary outcomes

• Percent change in bone formation marker, P1NP — up to 2 years

Countries

United States